News
VALN
5.75
+1.77%
0.10
Weekly Report: what happened at VALN last week (1021-1025)?
Weekly Report · 5d ago
Valneva’s Chikungunya Vaccine Gains Scientific Spotlight
TipRanks · 10/21 20:31
Weekly Report: what happened at VALN last week (1014-1018)?
Weekly Report · 10/21 09:16
Valneva Gains FDA Fast Track for Shigella Vaccine
TipRanks · 10/16 20:17
Valneva reports FDA Fast Track Designation for shigella vaccine candidate
TipRanks · 10/16 15:50
Weekly Report: what happened at VALN last week (1007-1011)?
Weekly Report · 10/14 09:19
Palo Alto Networks To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga · 10/11 13:04
Expert Ratings For Valneva
Benzinga · 10/11 12:01
Valneva Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 10/11 10:27
Valneva Price Target Cut to $20.00/Share From $23.00 by HC Wainwright & Co.
Dow Jones · 10/11 10:27
HC Wainwright & Co. Maintains Buy on Valneva, Lowers Price Target to $20
Benzinga · 10/11 10:22
Buy Rating for VALN: Strong Vaccine Pipeline and Financial Upside
TipRanks · 10/11 10:15
Valneva price target lowered to $20 from $23 at H.C. Wainwright
TipRanks · 10/11 10:05
Valneva Outlines Future Growth and Vaccine Pipeline
TipRanks · 10/10 20:57
VALNEVA SE - IF APPROVED AND COMMERCIALIZED BY OUR PARTNER PFIZER, GROUP SEES PROFITABILITY FROM 2027, ALSO SUPPORTED BY THE REVENUE GROWTH WE EXPECT FROM OR EXISTING PORTFOLIO OF TRAVEL VACCINES OVER THE YEARS TO COME
Reuters · 10/10 05:00
Weekly Report: what happened at VALN last week (0930-1004)?
Weekly Report · 10/07 09:18
Valneva Announces Investor Day to Showcase Vaccine Pipeline
TipRanks · 10/03 10:57
Weekly Report: what happened at VALN last week (0923-0927)?
Weekly Report · 09/30 09:17
Valneva’s Growth Prospects and Market Undervaluation Justify a Buy Rating
TipRanks · 09/26 08:59
In-Depth Examination Of 6 Analyst Recommendations For Valneva
Benzinga · 09/25 12:01
More
Webull provides a variety of real-time VALN stock news. You can receive the latest news about Valneva Se through multiple platforms. This information may help you make smarter investment decisions.
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.